Table 3.

Bias, limits of agreement, and correlation between single-beat full-volume 3DE and CMRI for RV volumes and EFs

Group	Measurements	Bias ± SD	Limits of agreement	r	P∗
All subjects	EDV (mL)	−2.3 ± 13.7	−29.1 to 24.5	0.97	<.0001
	ESV (mL)	5.2 ± 9.5	−13.4 to 23.9	0.98	<.0001
	SV (mL)	−7.5 ± 11.8	−30.6 to 15.7	0.94	<.0001
	EF (%)	−4.6 ± 6.9	−18.2 to 9.0	0.91	<.0001
PH	EDV (mL)	4.0 ± 13.1	−21.6 to 29.7	0.97	<.0001
	ESV (mL)	8.4 ± 10.6	−12. 3 to 29.1	0.98	<.0001
	SV (mL)	−4.3 ± 10.8	−25.5 to 17.0	0.82	<.0001
	EF (%)	−4.8 ± 8.3	−21.1 to 11.5	0.81	<.0001
Carcinoid heart disease	EDV (mL)	−3.1 ± 10.1	−22.9 to 16.8	0.99	<.0001
	ESV (mL)	5.4 ± 8.2	−10.6 to 21.4	0.96	<.0001
	SV (mL)	−8.6 ± 13.9	−35.9 to 18.6	0.95	<.0001
	EF (%)	−3.8 ± 4.1	−11.9 to 4.2	0.82	<.0001
Healthy volunteers	EDV (mL)	−11.9 ± 9.0	−29.5 to 5.8	0.94	<.0001
	ESV (mL)	−0.4 ± 6.7	−13.6 to 12.9	0.88	<.0001
	SV (mL)	−11.2 ± 10.1	−31.0 to 8.7	0.84	<.0001
	EF (%)	−3.9 ± 6.5	−16.6 to 8.8	0.51	.021
Carcinoid (no valvulopathy)	EDV (mL)	−10.1 ± 15.0	−39.6 to 19.4	0.84	.001
	ESV (mL)	2.1 ± 5.5	−8.7 to 12.9	0.92	<.0001
	SV (mL)	−12.2 ± 12.3	−36.3 to 11.9	0.53	.096
	EF (%)	−6.2 ± 5.6	−17.1 to 4.7	0.69	.019

ESV, End-systolic volume.

^∗Pearson correlation coefficient.